This article is more than 5 years old. Information may no longer be current.
New class of anti-angiogenic drugs under development
Click Here to Manage Email Alerts
 Hugo Quiroz-Mercado |
ORLANDO, Fla. — Integrin peptide therapy is on its way as a potential newcomer to the armamentarium of therapeutics used to treat vascular eye disease, according to a speaker here who delivered safety and efficacy data after conclusion of a phase 1 study. "We have shown an emerging new class of treatment for vascular eye disease," Hugo Quiroz-Mercado, MD, reported at the Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
ALG-1001, which is being developed by Allegro Ophthalmics, is a first in class oligopeptide that binds to multiple angiogenic pathways, Dr. Quiroz-Mercado, said. The oligopeptide turns off the angiogenic cascade at its source and provides long-lasting effects, Dr. Quiroz-Mercado said.
"In phase 1 study, we observed that ALG is a safe treatment," Dr. Quiroz-Mercado said, and the treatment was efficacious in more than 50% of patients. Clinical benefit lasted 90 days, he said.
Phase 2 trial in 75 wet AMD patients is planned in the U.S. in 2012.
- Disclosure: Dr. Quiroz-Mercado has financial interest in Allegro Ophthalmics LLC.